In 2026, Spravato (esketamine) billing continues to be one of the most complex areas in behavioral health revenue cycle management due to strict payer rules, REMS program requirements, and multi-component reimbursement structures. Hospitals and behavioral health providers must follow precise workflows to ensure clean claims and avoid delays or denials. This is where specialized spravato billing services play a critical role in optimizing reimbursement outcomes.

Understanding Spravato Billing in 2026

Spravato is not billed like a standard antidepressant treatment. Instead, it is billed as a supervised, in-clinic administration service that includes drug cost, monitoring time, and clinical oversight. In 2026, most insurance payers still require separate handling of drug administration and observation services, making accurate coding essential.

The foundation of billing lies in correct spravato billing codes, which typically include HCPCS codes such as G2082 and G2083 (depending on dosing and administration session length), along with appropriate diagnosis codes for treatment-resistant depression. Hospitals must also ensure that documentation supports medical necessity, prior authorization approval, and REMS program compliance.

Step-by-Step Spravato Billing Process

A structured approach is essential for successful reimbursement. A reliable spravato billing guide typically includes the following steps:

1. Eligibility Verification
   Before treatment begins, insurance eligibility must be confirmed, including whether Spravato is covered under medical or pharmacy benefits.

2. Prior Authorization Approval
   Most payers require prior authorization before the first dose. Missing this step is one of the most common spravato billing issues.

3. REMS Compliance Documentation
   Providers must ensure that both patient and clinic are certified under the REMS program, and monitoring protocols are documented.

4. Accurate Coding and Claim Submission
   Using correct spravato billing codes, hospitals submit claims for drug administration, observation time, and associated services.

5. Claims Scrubbing and Review
   Claims should be checked for errors such as mismatched units, missing modifiers, or incorrect payer rules before submission.

6. Denial Management and Appeals
   If claims are denied, structured appeal processes must be followed using clinical documentation and payer guidelines.

Common Spravato Billing Issues in 2026

Despite improvements in revenue cycle systems, hospitals still face recurring challenges. Some of the most frequent spravato billing issues include:

• Prior authorization delays or rejections

• Incomplete documentation of monitoring time

• Incorrect use of HCPCS codes

• Confusion between pharmacy benefit vs medical benefit billing

• Denials due to lack of REMS compliance proof

• Underpayment due to incorrect session bundling

These issues can significantly reduce hospital revenue if not addressed through proper workflow management.

Spravato Reimbursement Optimization

A structured spravato reimbursement guide focuses on maximizing reimbursement by ensuring every billable component is captured correctly. This includes:

• Accurate time-based billing for observation periods

• Proper separation of drug cost and administration services

• Regular payer policy updates tracking

• Automated claims scrubbing systems

• Use of experienced billing teams familiar with behavioral health RCM

Many hospitals now rely on outsourced or specialized spravato billing services to improve first-pass claim acceptance rates and reduce administrative burden.

Final Thoughts

In 2026, Spravato billing requires precision, compliance, and strong revenue cycle coordination. With evolving payer requirements and strict documentation standards, hospitals must adopt a proactive approach. By following a structured spravato billing guide, addressing common spravato billing issues, and leveraging expert-driven spravato billing services, healthcare providers can significantly improve reimbursement outcomes and reduce revenue leakage.